tradingkey.logo


tradingkey.logo


Amphastar Pharmaceuticals Inc

AMPH
19.010USD
-0.520-2.66%
āļ›āļīāļ” 03/27, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
825.15MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
9.06P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Amphastar Pharmaceuticals Inc āļšāļĢāļīāļĐāļąāļ—

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

āļ‚āđ‰āļ­āļĄāļđāļĨ Amphastar Pharmaceuticals Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™AMPH
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Amphastar Pharmaceuticals Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 25, 2014
āļ‹āļĩāļ­āļĩāđ‚āļ­Zhang (Yongfeng Yongfeng)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™2028
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jun 25
āļ—āļĩāđˆāļ­āļĒāļđāđˆ11570 6th St
āđ€āļĄāļ·āļ­āļ‡RANCHO CUCAMONGA
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ91730
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ19099809484
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://amphastar.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™AMPH
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 25, 2014
āļ‹āļĩāļ­āļĩāđ‚āļ­Zhang (Yongfeng Yongfeng)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Amphastar Pharmaceuticals Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
230.62K
+14.53%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.82%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
104.97K
+47.19%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
68.29K
-6.10%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+65.35%
Dr. Yongfeng (Jack) Zhang, Ph.D.
Dr. Yongfeng (Jack) Zhang, Ph.D.
President, Chief Executive Officer, Chief Scientific Officer, Director
President, Chief Executive Officer, Chief Scientific Officer, Director
--
--
Dr. Ziping (Mary) Luo, Ph.D.
Dr. Ziping (Mary) Luo, Ph.D.
Chairman of the Board, Chief Operating Officer, Chief Scientist
Chairman of the Board, Chief Operating Officer, Chief Scientist
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Dr. Michael A. Zasloff, M.D., Ph.D.
Dr. Michael A. Zasloff, M.D., Ph.D.
Independent Director
Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
230.62K
+14.53%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.82%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
104.97K
+47.19%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
68.29K
-6.10%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+65.35%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
180.28M
93.97%
France
9.68M
5.05%
China
1.88M
0.98%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļ.āļž.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļ.āļž.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Applied Physics & Chemistry Laboratories, Inc.
15.05%
BlackRock Institutional Trust Company, N.A.
10.90%
Zhang (Jack Yongfeng)
6.10%
The Vanguard Group, Inc.
5.70%
TD Asset Management Inc.
4.33%
āļ­āļ·āđˆāļ™ āđ†
57.93%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Applied Physics & Chemistry Laboratories, Inc.
15.05%
BlackRock Institutional Trust Company, N.A.
10.90%
Zhang (Jack Yongfeng)
6.10%
The Vanguard Group, Inc.
5.70%
TD Asset Management Inc.
4.33%
āļ­āļ·āđˆāļ™ āđ†
57.93%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
42.40%
Investment Advisor/Hedge Fund
24.78%
Corporation
15.05%
Individual Investor
10.11%
Hedge Fund
4.92%
Research Firm
2.85%
Pension Fund
1.13%
Bank and Trust
0.36%
Family Office
0.27%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.86%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.94M
10.75%
-185.58K
-3.62%
Sep 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.71%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.61M
5.68%
-55.91K
-2.10%
Sep 30, 2025
TD Asset Management Inc.
1.93M
4.2%
-103.04K
-5.06%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.76M
3.82%
+128.78K
+7.92%
Sep 30, 2025
State Street Investment Management (US)
1.50M
3.27%
-75.49K
-4.79%
Sep 30, 2025
Fuller & Thaler Asset Management Inc.
1.35M
2.95%
+90.16K
+7.13%
Sep 30, 2025
Marshall Wace LLP
874.07K
1.9%
+25.38K
+2.99%
Sep 30, 2025
Epoch Investment Partners, Inc.
1.13M
2.47%
-107.38K
-8.65%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Invesco Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.25%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.38%
Invesco S&P SmallCap 600 GARP ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.12%
Acquirers Small and Micro Deep Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.77%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.56%
First Trust Small Cap Value AlphaDEX Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.5%
Distillate Small/Mid Cash Flow ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.45%
VictoryShares Small Cap Free Cash Flow ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.37%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™